JP2006515593A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006515593A5 JP2006515593A5 JP2004563345A JP2004563345A JP2006515593A5 JP 2006515593 A5 JP2006515593 A5 JP 2006515593A5 JP 2004563345 A JP2004563345 A JP 2004563345A JP 2004563345 A JP2004563345 A JP 2004563345A JP 2006515593 A5 JP2006515593 A5 JP 2006515593A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- amino
- carbamoyl
- heterocyclyl
- alkanoylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 114
- 229910052757 nitrogen Inorganic materials 0.000 claims 22
- 229910052739 hydrogen Inorganic materials 0.000 claims 19
- 239000001257 hydrogen Substances 0.000 claims 19
- 125000000623 heterocyclic group Chemical group 0.000 claims 17
- 125000005236 alkanoylamino group Chemical group 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 16
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 16
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 14
- -1 trifluoromethoxy, cyano, nitro, hydroxy, amino, carboxy, carbamoyl Chemical group 0.000 claims 14
- 125000005843 halogen group Chemical group 0.000 claims 13
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 12
- 125000003282 alkyl amino group Chemical group 0.000 claims 12
- 229910052760 oxygen Inorganic materials 0.000 claims 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 11
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 10
- 125000001424 substituent group Chemical group 0.000 claims 10
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 125000004414 alkyl thio group Chemical group 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 229910052717 sulfur Inorganic materials 0.000 claims 9
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- 150000002431 hydrogen Chemical group 0.000 claims 8
- 125000004423 acyloxy group Chemical group 0.000 claims 7
- 125000005153 alkyl sulfamoyl group Chemical group 0.000 claims 7
- 125000001589 carboacyl group Chemical group 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 7
- 125000003302 alkenyloxy group Chemical group 0.000 claims 6
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 6
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 125000005133 alkynyloxy group Chemical group 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000006319 alkynyl amino group Chemical group 0.000 claims 2
- 125000001769 aryl amino group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- GOJZHNWOESVAEU-UHFFFAOYSA-N 4-[2-(6-phenylimidazo[2,1-b][1,3]thiazol-5-yl)ethenyl]pyrimidin-2-amine Chemical compound NC1=NC=CC(C=CC=2N3C=CSC3=NC=2C=2C=CC=CC=2)=N1 GOJZHNWOESVAEU-UHFFFAOYSA-N 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 108010090091 TIE-2 Receptor Proteins 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 150000001335 aliphatic alkanes Chemical class 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 230000001772 anti-angiogenic effect Effects 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 210000000013 bile duct Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 210000003292 kidney cell Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0230089.5A GB0230089D0 (en) | 2002-12-24 | 2002-12-24 | Therapeutic agents |
| PCT/GB2003/005568 WO2004058776A1 (en) | 2002-12-24 | 2003-12-19 | Therapeutic agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006515593A JP2006515593A (ja) | 2006-06-01 |
| JP2006515593A5 true JP2006515593A5 (https=) | 2006-11-09 |
Family
ID=9950374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004563345A Pending JP2006515593A (ja) | 2002-12-24 | 2003-12-19 | 治療剤 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20060069109A1 (https=) |
| EP (1) | EP1575963B1 (https=) |
| JP (1) | JP2006515593A (https=) |
| KR (1) | KR20050087852A (https=) |
| CN (1) | CN1751052A (https=) |
| AT (1) | ATE394403T1 (https=) |
| AU (1) | AU2003295135A1 (https=) |
| BR (1) | BR0317708A (https=) |
| CA (1) | CA2508917A1 (https=) |
| DE (1) | DE60320849D1 (https=) |
| ES (1) | ES2305548T3 (https=) |
| GB (1) | GB0230089D0 (https=) |
| MX (1) | MXPA05006921A (https=) |
| NO (1) | NO20052989L (https=) |
| WO (1) | WO2004058776A1 (https=) |
| ZA (1) | ZA200504827B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7776869B2 (en) | 2004-10-18 | 2010-08-17 | Amgen Inc. | Heteroaryl-substituted alkyne compounds and method of use |
| GB0502418D0 (en) * | 2005-02-05 | 2005-03-16 | Astrazeneca Ab | Compounds |
| AU2015210454B2 (en) * | 2005-12-23 | 2016-10-27 | Takeda Pharmaceuticals U.S.A., Inc. | Bicyclic heteroaryl compounds |
| SI1973545T1 (sl) * | 2005-12-23 | 2013-04-30 | Ariad Pharmaceuticals, Inc. | Spojine bicikličnega heteroarila |
| EA034598B1 (ru) | 2005-12-23 | 2020-02-25 | Ариад Фармасьютикалз, Инк. | Применение бициклических гетероарильных соединений для лечения рака |
| US8278307B2 (en) | 2006-05-08 | 2012-10-02 | Ariad Pharmaceuticals, Inc. | Monocyclic Heteroaryl compounds |
| CN103435595A (zh) | 2006-05-08 | 2013-12-11 | 阿里亚德医药股份有限公司 | 炔类杂芳基化合物 |
| WO2008076883A2 (en) | 2006-12-15 | 2008-06-26 | Abraxis Bioscience, Inc. | Triazine derivatives and their therapeutical applications |
| EP2307456B1 (en) | 2008-06-27 | 2014-10-15 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
| CA2743449C (en) | 2008-11-12 | 2016-10-18 | Ariad Pharmaceuticals, Inc. | Pyrazinopyrazines and derivatives as kinase inhibitors |
| JP5785940B2 (ja) | 2009-06-09 | 2015-09-30 | アブラクシス バイオサイエンス， エルエルシー | トリアジン誘導体類及びそれらの治療応用 |
| EP2440053A4 (en) | 2009-06-09 | 2012-10-31 | California Capital Equity Llc | BENZYL SUBSTITUTED TRIAZINE DERIVATIVES AND THERAPEUTIC APPLICATIONS THEREOF |
| EP2308866A1 (de) | 2009-10-09 | 2011-04-13 | Bayer CropScience AG | Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide |
| EP2508511A1 (en) * | 2011-04-07 | 2012-10-10 | Laboratoire Biodim | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
| MX2014014308A (es) * | 2012-05-30 | 2015-02-12 | Hoffmann La Roche | Pirrolidino heterociclos. |
| CA3022250A1 (en) | 2012-12-12 | 2014-06-12 | Ariad Pharmaceuticals, Inc. | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride |
| US12570660B2 (en) | 2019-08-16 | 2026-03-10 | Cyclacel Pharmaceuticals, Inc | Process for the preparation of a pyrimidino-diazepine derivative |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003509428A (ja) * | 1999-09-17 | 2003-03-11 | アボツト・ゲー・エム・ベー・ハー・ウント・コンパニー・カーゲー | 治療薬としてのピラゾロピリミジン |
| AU1529901A (en) * | 1999-11-22 | 2001-06-04 | Smithkline Beecham Plc | Compounds |
| ATE365730T1 (de) * | 2000-11-20 | 2007-07-15 | Smithkline Beecham Corp | Neuartige verbindungen |
| DE60304718T2 (de) * | 2002-08-06 | 2007-04-26 | Astrazeneca Ab | Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität |
-
2002
- 2002-12-24 GB GBGB0230089.5A patent/GB0230089D0/en not_active Ceased
-
2003
- 2003-12-19 CN CNA2003801098327A patent/CN1751052A/zh active Pending
- 2003-12-19 EP EP03786136A patent/EP1575963B1/en not_active Expired - Lifetime
- 2003-12-19 BR BR0317708-4A patent/BR0317708A/pt not_active Application Discontinuation
- 2003-12-19 MX MXPA05006921A patent/MXPA05006921A/es unknown
- 2003-12-19 JP JP2004563345A patent/JP2006515593A/ja active Pending
- 2003-12-19 AU AU2003295135A patent/AU2003295135A1/en not_active Abandoned
- 2003-12-19 US US10/540,348 patent/US20060069109A1/en not_active Abandoned
- 2003-12-19 DE DE60320849T patent/DE60320849D1/de not_active Expired - Fee Related
- 2003-12-19 KR KR1020057011870A patent/KR20050087852A/ko not_active Withdrawn
- 2003-12-19 AT AT03786136T patent/ATE394403T1/de not_active IP Right Cessation
- 2003-12-19 CA CA002508917A patent/CA2508917A1/en not_active Abandoned
- 2003-12-19 WO PCT/GB2003/005568 patent/WO2004058776A1/en not_active Ceased
- 2003-12-19 ES ES03786136T patent/ES2305548T3/es not_active Expired - Lifetime
-
2005
- 2005-06-13 ZA ZA200504827A patent/ZA200504827B/en unknown
- 2005-06-17 NO NO20052989A patent/NO20052989L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006515593A5 (https=) | ||
| US12433867B2 (en) | Pharmaceutical composition comprising FLT3 inhibitor and hypomethylating agent for treating acute myeloid leukemia | |
| US12350265B2 (en) | Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents | |
| FI3784664T3 (fi) | 2-aminopyridiini- tai 2-aminopyrimidiinijohdannaisia sykliiniriippuvaisen kinaasin estäjinä | |
| FI4003989T3 (fi) | 6,7-dihydro-5h-pyrido[2,3-c]pyridatsiinijohdannaisia ja niihin liittyviä yhdisteitä bcl-xl-proteiinin inhibiittoreina ja proapoptoottisina aineina syövän hoitamiseksi | |
| RU2021102253A (ru) | Деструкторы белка mdm2 | |
| CO5690594A2 (es) | Derivados de quinazolina como inhibidores de tirosina cinasa | |
| RU2010126050A (ru) | Антибактериальные нуклеозидные соединения | |
| IL276152B2 (en) | Estrogen receptor-modulating compounds | |
| KR20180013850A (ko) | 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린의 용도 | |
| JP2006525296A5 (https=) | ||
| WO2016142312A1 (en) | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations | |
| EP3928780A1 (en) | Pharmaceutical composition comprising flt3 inhibitor and hypomethylating agent for treating acute myeloid leukemia | |
| RU2007134105A (ru) | Производные 4-оксохиназолин-3-ил-бензамида для лечения цитокиновых заболеваний | |
| US11806339B2 (en) | Combination therapy of Axl inhibitor and EGFR tyrosine kinase inhibitor | |
| JP2020503376A5 (https=) | ||
| RU2006100484A (ru) | Соединения, обладающие ингибирующей активностью в отношении фосфатидилинозит-3-киназы, фармацевтическая композиция, способ определения эффективности этих соединений, способ лечения нарушений (варианты) и способ изменения передачи сигнала в клетках | |
| RU2013120357A (ru) | Фармацевтические комбинации | |
| KR20210038366A (ko) | Flt3 저해제 및 mdm2 저해제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물 | |
| US20200246284A1 (en) | Use of Ureidomustine (BO-1055) in Cancer Treatment | |
| KR20200102948A (ko) | Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물 | |
| RU2007106933A (ru) | Ингибиторы hsp90 | |
| MX2024014790A (es) | Agonistas del receptor macrocíclico de orexina y sus usos | |
| HK40066212A (en) | Pharmaceutical composition comprising flt3 inhibitor and hypomethylating agent for treating acute myeloid leukemia | |
| JP2001122780A (ja) | 抗悪性腫瘍薬 |